OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Table. 1.

Table. 1.

Baseline characteristics of patients with NAFLD

Clinical characteristics Total (N = 113)
Age (yr) 47.0 [30.0; 61.0]*
Sex
Male 58 (51.3%)
Female 55 (48.7%)
Body weight (kg) 76.0 [67.8; 89.0]*
Height (m) 1.6 ± 0.1
BMI (kg/m2) 28.7 [26.0; 31.2]*
DM 36 (31.9%)
M2BPGi 0.6 [0.3; 1.1]*
Steatosis
1: 5–33% 45 (39.8%)
2: 33–66% 38 (33.6%)
3: > 66% 30 (26.5%)
Lobular inflammation
0: none 3 (2.7%)
1: < 2 foci per 200 × field (%) 63 (55.8%)
2: 2–4 foci per 200 × field (%) 42 (37.2%)
3: > 4 foci per 200 × field (%) 5 (4.4%)
Ballooning
0: none 26 (23.0%)
1: mild, few 39 (34.5%)
2: moderate to marked, many 48 (42.5%)
Fibrosis
0: none 19 (16.8%)
1a: mild, zone 3, perisinusoidal 26 (23.0%)
1b: moderate, zone 3, perisinusoidal 6 (5.3%)
1c: portal/periportal 2 (1.8%)
2: perisinusoidal and portal/periportal 27 (23.9%)
3: bridging fibrosis 20 (17.7%)
4: cirrhosis 13 (11.5%)
NAS 4 (4; 5)*
1–4 57 (50.4%)
5–8 56 (49.6%)

*median [25–75% interquartile range].

Abbreviations: BMI, body mass index; DM, diabetes mellitus; M2BPGi, Mac-2 binding protein glycosylation isomer; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD activity score.

Ann Lab Med 2021;41:302~309 https://doi.org/10.3343/alm.2021.41.3.302

© Ann Lab Med